Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIA Single-Arm Study of Treatment of Patients With Advanced Liver Cancer With a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody

Next Previous
X
Search
Trial Profile

Phase IIA Single-Arm Study of Treatment of Patients With Advanced Liver Cancer With a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tirapazamine (Primary) ; Nivolumab
  • Indications Gastric cancer; Liver cancer
  • Focus Therapeutic Use
  • Acronyms TATE-PD1
  • Sponsors Teclison

    • Most Recent Events

    • 18 Sep 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
    • 18 Sep 2023 Planned primary completion date changed from 31 May 2024 to 31 Dec 2024.
    • 13 Apr 2022 Planned number of patients changed from 80 to 54.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top